Fondaparinux Dosing for Different Medical Conditions
Fondaparinux is an anticoagulant medication used to prevent and treat blood clots. Its dosage varies depending on the specific medical condition it is being used for.
What is the typical dose for preventing blood clots after surgery?
For the prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing hip fracture surgery, hip replacement surgery, or knee replacement surgery, the standard dose of fondaparinux is 2.5 mg once daily administered subcutaneously [1]. This regimen typically begins 2 to 6 hours after surgery and continues for 5 to 9 days, or until the patient is fully ambulatory [1].
How is fondaparinux dosed for existing deep vein thrombosis or pulmonary embolism?
When treating established DVT or PE, the dosage of fondaparinux is weight-based. Patients weighing 50 kg or more typically receive 7.5 mg subcutaneously once daily [1]. For patients weighing less than 50 kg, the dose is adjusted to 5 mg subcutaneously once daily [1]. This treatment generally continues for a minimum of 5 days, with the duration extended based on the patient's risk factors and response to therapy, and in conjunction with oral anticoagulant therapy [1].
What is the recommended dosage for patients with kidney problems?
Fondaparinux is primarily eliminated by the kidneys, and its dosage requires adjustment in patients with impaired renal function. For individuals with moderate renal impairment (creatinine clearance between 30-50 mL/min), the dose is typically reduced to 5 mg once daily [1]. In patients with severe renal impairment (creatinine clearance less than 30 mL/min), fondaparinux is generally not recommended due to the lack of sufficient data and the increased risk of bleeding [1].
Are there any specific dosing considerations for elderly patients?
While there are no specific dose adjustments for elderly patients solely based on age, it is important to consider that elderly individuals may have reduced renal function, which would necessitate a dose adjustment as described for patients with kidney problems [1].
How is fondaparinux administered?
Fondaparinux is administered as a subcutaneous injection, meaning it is injected into the fatty tissue just under the skin [1]. It is typically given once a day.
When does the patent for fondaparinux expire?
Information regarding specific patent expiry dates for fondaparinux can be found through specialized patent databases. DrugPatentWatch.com tracks patent information for various drugs, including their expiry dates and any related litigation [2].
What are the main side effects associated with fondaparinux?
The most significant risk associated with fondaparinux is bleeding [1]. Other potential side effects include anemia, nausea, and minor irritation at the injection site [1]. Patients should report any signs of unusual bruising, bleeding, or other concerning symptoms to their healthcare provider immediately.